Get the Stockscreener App
3.10
7.45%
0.215
Pre-market:
3.10
Esperion Therapeutics Inc stock is traded at $3.10, with a volume of 7.90M.
It is up +7.45% in the last 24 hours and up +22.53% over the past month.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
See More
Previous Close:
$2.885
Open:
$2.88
24h Volume:
7.90M
Relative Volume:
1.17
Market Cap:
$625.03M
Revenue:
$116.33M
Net Income/Loss:
$-209.25M
P/E Ratio:
-1.4623
EPS:
-2.12
Net Cash Flow:
$-135.49M
1W Performance:
+8.77%
1M Performance:
+22.53%
6M Performance:
+288.37%
1Y Performance:
+23.02%
1-Day Range:
$2.84
$3.115
1-Week Range:
$2.4235
$3.115
52-Week Range:
$0.6925
$3.94
Esperion Therapeutics Inc Stock (ESPR) Company Profile
Name
Esperion Therapeutics Inc
Sector
Phone
734-887-3903
Address
3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR, MI
Compare ESPR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ESPR
Esperion Therapeutics Inc
|
3.10 | 682.76M | 116.33M | -209.25M | -135.49M | -2.12 |
|
ZTS
Zoetis Inc
|
120.12 | 52.79B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.01 | 43.31B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.85 | 42.61B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
25.13 | 27.83B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
459.21 | 19.54B | 3.08B | 1.24B | 1.07B | 25.61 |
Esperion Therapeutics Inc Stock (ESPR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-18-24 | Initiated | Goldman | Neutral |
| Dec-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-20-24 | Downgrade | BofA Securities | Neutral → Underperform |
| Jan-03-24 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-20-23 | Resumed | JP Morgan | Neutral |
| Aug-01-23 | Upgrade | Northland Capital | Under Perform → Market Perform |
| Jun-15-23 | Upgrade | BofA Securities | Underperform → Buy |
| Mar-16-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Mar-16-23 | Downgrade | Northland Capital | Market Perform → Under Perform |
| Mar-07-23 | Upgrade | Credit Suisse | Underperform → Neutral |
| Feb-27-23 | Resumed | BofA Securities | Neutral |
| Feb-24-23 | Upgrade | Jefferies | Hold → Buy |
| Feb-03-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Aug-03-22 | Downgrade | Credit Suisse | Neutral → Underperform |
| May-05-22 | Upgrade | JP Morgan | Underweight → Neutral |
| Mar-10-22 | Initiated | H.C. Wainwright | Buy |
| Oct-19-21 | Downgrade | Credit Suisse | Outperform → Neutral |
| Oct-14-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| May-05-21 | Downgrade | Stifel | Buy → Hold |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Mar-11-21 | Initiated | Morgan Stanley | Equal-Weight |
| Feb-12-21 | Downgrade | Jefferies | Buy → Hold |
| Feb-09-21 | Downgrade | Goldman | Neutral → Sell |
| Jan-15-21 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-10-20 | Upgrade | Credit Suisse | Neutral → Outperform |
| Sep-29-20 | Resumed | JP Morgan | Underweight |
| Aug-11-20 | Downgrade | Credit Suisse | Outperform → Neutral |
| Apr-01-20 | Resumed | BofA/Merrill | Buy |
| Mar-17-20 | Upgrade | Citigroup | Neutral → Buy |
| Feb-24-20 | Downgrade | Northland Capital | Outperform → Market Perform |
| Feb-14-20 | Downgrade | Citigroup | Buy → Neutral |
| Sep-16-19 | Upgrade | Goldman | Sell → Neutral |
| May-29-19 | Downgrade | Goldman | Neutral → Sell |
| May-06-19 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Apr-26-19 | Upgrade | Goldman | Sell → Neutral |
| Mar-13-19 | Upgrade | JP Morgan | Underweight → Neutral |
| Jan-07-19 | Reiterated | Needham | Strong Buy |
| Dec-13-18 | Initiated | Goldman | Sell |
| Oct-29-18 | Upgrade | Northland Capital | Market Perform → Outperform |
| Oct-16-18 | Initiated | BTIG Research | Buy |
| Aug-17-18 | Upgrade | Citigroup | Neutral → Buy |
| Jul-11-18 | Downgrade | Northland Capital | Outperform → Market Perform |
| May-03-18 | Downgrade | JP Morgan | Neutral → Underweight |
| May-02-18 | Downgrade | BofA/Merrill | Buy → Underperform |
View All
Esperion Therapeutics Inc Stock (ESPR) Latest News
Why retail investors favor Esperion Therapeutics Inc. stockEarnings Summary Report & Accurate Entry/Exit Alerts - newser.com
Will earnings trigger a reversal in Esperion Therapeutics Inc.July 2025 Intraday Action & AI Powered Buy and Sell Recommendations - newser.com
Can Esperion Therapeutics Inc. stock double in next 5 yearsJuly 2025 Market Mood & Verified Technical Trade Signals - newser.com
Esperion Therapeutics: Biotech With Limited Upside, Hold - Seeking Alpha
How Esperion Therapeutics Inc. stock benefits from global expansion2025 Trading Recap & AI Driven Price Predictions - newser.com
Why analysts raise outlook for Esperion Therapeutics Inc. (0ET) stockStop Loss & Momentum Based Trading Signals - newser.com
Can volume confirm reversal in Esperion Therapeutics Inc.Dollar Strength & Verified Chart Pattern Trade Signals - newser.com
What drives Esperion Therapeutics Inc 0ET stock priceCash Flow Trends & Free Daily Top Stock Picks for All Investors - earlytimes.in
Can Esperion Therapeutics Inc. stock reach $100 price targetWeekly Investment Report & Weekly Hot Stock Watchlists - newser.com
Esperion Announces New Data from CLEAR Outcomes Highlighting Value of NEXLETOL® (bempedoic acid) in Oral and Poster Presentations at the AHA Scientific Sessions 2025 - The Manila Times
Esperion (NASDAQ: ESPR) reports 42% lower VTE risk with bempedoic acid in CLEAR Outcomes - Stock Titan
Esperion Therapeutics: Still An Attractive Risk/Reward Narrative As The Earnings Clock Ticks Toward Profitability - Seeking Alpha
Esperion outlines Vision 2040 and expects U.S. guideline inclusion in early 2026 while sustaining double-digit prescription growth - MSN
Will Esperion Therapeutics Inc. stock outperform international peers2025 Volume Leaders & Real-Time Volume Analysis - newser.com
Esperion Therapeutics Reports Strong Q3 Revenue Growth - MSN
Why Esperion Therapeutics Inc. is moving todayWeekly Trade Review & Capital Efficiency Focused Strategies - newser.com
Tracking the Narrative for Esperion Therapeutics as Analyst Optimism Grows Amid Shifting Fundamentals - Yahoo Finance
Will Esperion Therapeutics Inc. stock gain from lower inflation2025 Performance Recap & AI Driven Stock Reports - newser.com
ESPR's Q3 Earnings Lag Estimates, Revenues Rise Y/Y, Stock Down - MSN
Esperion Therapeutics (ESPR) Reports Q3 Loss, Tops Revenue Estimates - MSN
Esperion Therapeutics Inc. (ESPR) Stock Price | Live Quotes & Charts | NSD - StocksToTrade
Relative strength of Esperion Therapeutics Inc. in sector analysisGlobal Markets & Expert Approved Trade Ideas - newser.com
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q3 2025 Earnings Call Transcript - Insider Monkey
Esperion Therapeutics: Q3 Earnings Snapshot - Connecticut Post
Esperion Therapeutics Inc (ESPR) Q3 2025 Earnings Call Highlights: Revenue Surge and Strategic ... By GuruFocus - Investing.com Canada
Why Esperion Therapeutics Inc. stock is favored by top institutionsRecession Risk & Daily Growth Stock Investment Tips - newser.com
Smart tools for monitoring Esperion Therapeutics Inc.’s price actionM&A Rumor & Long-Term Safe Investment Ideas - newser.com
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
Esperion (NASDAQ: ESPR) grants 77,650 RSUs under inducement plan to 23 new employees - Stock Titan
[10-Q] Esperion Therapeutics, Inc. Quarterly Earnings Report | ESPR SEC FilingForm 10-Q - Stock Titan
Esperion Therapeutics Inc (ESPR) Q3 2025 Earnings Call Highlights: Revenue Surge and Strategic ... - Yahoo Finance
Transcript : Esperion Therapeutics, Inc., Q3 2025 Earnings Call, Nov 06, 2025 - MarketScreener
Should you wait for a breakout in Esperion Therapeutics Inc.Portfolio Growth Summary & Stock Timing and Entry Methods - newser.com
Esperion Q3 2025 slides: 69% revenue growth overshadowed by earnings miss - Investing.com
Esperion’s Revenue Climbs As It Eyes Long-Term Market Defense - Finimize
Earnings call transcript: Esperion Therapeutics Q3 2025 results miss forecasts - Investing.com India
Esperion Therapeutics Inc Stock (ESPR) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.17%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):